That’s the question that led a group of researchers from the Van Andel Institute to uncover a new key piece in the complex puzzle of cancer immunotherapy. Their study, recently highlighted in Medical Xpress (June 2025), reveals that a molecule called PTGIR —the prostacyclin receptor— acts as an internal brake within T cells, preventing them from expanding and acting at full capacity inside the tumor environment. This finding not only broadens our understanding of why some T cells lose effectiveness inside tumors but also suggests a new therapeutic target that could radically enhance current immunological treatments.

Cytotoxic T cells are one of the main players in the adaptive immune system. They are responsible for patrolling the body in search of abnormal cells, including those that make up a tumor. However, in many cancer patients, these cells infiltrate the tumor but become “exhausted”—that is, biologically deactivated. This deactivation has been attributed to multiple immunosuppressive mechanisms, including the well-known immune checkpoints like PD‑1 and CTLA‑4. What the new study adds is an understanding of a deeper level of intracellular regulation: not only are there external signals that turn T cells off, but there are also internal mechanisms—like PTGIR activity—that restrict their activation even if the external inhibitory signals are blocked.

PTGIR is a G protein-coupled receptor that is activated by prostacyclin, a molecule typically associated with vasodilation and anti-platelet aggregation. However, in this new context, PTGIR appears to function as a sort of cellular thermostat: it regulates the response of T cells in conditions of chronic inflammation, such as those found within the tumor microenvironment. When active, PTGIR limits the proliferation of T cells and reduces the release of pro-inflammatory molecules like interferon-gamma (IFN‑γ) and perforin, which are essential to destroy tumor cells. This brake, though useful to prevent out-of-control autoimmune responses, becomes a significant obstacle in the context of cancer.

In preclinical models, researchers blocked PTGIR function and observed an immediate effect: T cells not only increased in number but also regained their ability to strongly attack cancer cells. Cytokine production was restored, their capacity to kill target cells was amplified, and in some cases, anti-tumor responses improved in mouse models. These results are particularly promising because they point to a different approach from traditional immunotherapies like immune checkpoint inhibitors. That is, rather than just removing external brakes, this strategy lifts an internal brake, reactivating T cells from their molecular core.

This discovery gains even more relevance when we consider that many patients do not respond adequately to available immunotherapeutic treatments. Even in so-called “hot” tumors—those with T cell infiltration—the immune system can fail due to functional exhaustion of those cells. Blocking PTGIR could offer a way to revitalize those exhausted cells, turning them once again into effective fighters. Moreover, since this mechanism acts from within the T cell, it could be combined with other external therapies, such as neoantigen vaccines, CAR‑T therapies, or even the aforementioned checkpoint inhibitors.

Of course, we are still looking at preclinical results, and much remains to be studied before this strategy can be translated to clinical practice. One of the main challenges will be ensuring that PTGIR inhibition does not generate severe side effects, especially those related to overstimulation of the immune system, which could lead to autoimmunity. It will also be crucial to identify which patient subpopulations would benefit most from this approach: Will it be useful in all types of cancer? Will it depend on the tumor’s mutational burden or the cytokine profile of the microenvironment?

Figure 1. PTGIR activation suppresses T cell function and promotes exhaustion, while its inhibition restores cytotoxic activity and enhances antitumor responses.

These types of questions will be key for the development of future clinical trials. Nonetheless, the discovery of PTGIR as a negative intracellular regulator is an innovative piece in the puzzle of cancer treatment. As immunotherapy continues to evolve, we need approaches that not only “unlock” the immune system but also reprogram it from within. This study opens precisely that possibility: a deeper, smarter, and more personalized immunotherapy.

In short, releasing the molecular brake on T cells could be one of the next major advances in the fight against cancer. Perhaps soon, oncologists won’t just talk about immune checkpoints, but also about intracellular switches like PTGIR, whose silencing could rewrite the fate of an immune cell… and of a patient.

Main Reference:

Dahabieh, M. S., DeCamp, L. M., Oswald, B. M., Kitchen-Goosen, S. M., Fu, Z., Vos, M., Compton, S. E., Longo, J., Foy, N. M., Williams, K. S., Ellis, A. E., Johnson, A., Sodiya, I., Vincent, M., Lee, H., Yao, C., Wu, T., Sheldon, R. D., Krawczyk, C. M., & Jones, R. G. (2025). The prostacyclin receptor PTGIR is a NRF2-dependent regulator of CD8+ T cell exhaustion. Nature immunology, 26(7), 1139–1151. https://doi.org/10.1038/s41590-025-02185-9

Other References:

Wherry, E. J., & Kurachi, M. (2015). Molecular and cellular insights into T cell exhaustion. Nature reviews. Immunology, 15(8), 486–499. https://doi.org/10.1038/nri3862

Pardoll D. M. (2012). The blockade of immune checkpoints in cancer immunotherapy. Nature reviews. Cancer, 12(4), 252–264. https://doi.org/10.1038/nrc3239

Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017). Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell, 168(4), 707–723. https://doi.org/10.1016/j.cell.2017.01.017